Sodium zirconium cyclosilicate and patiromer are commonly prescribed to chronic kidney disease patients because of their property of binding to which one of the following electrolytes?
Potassium
Sodium zirconium cyclosilicate and patiromer are both non-absorbed potassium-binding agents used for the management of hyperkalaemia in CKD patients. They exchange other cations for potassium in the gastrointestinal tract, thereby lowering serum potassium.
Similar Questions
Calcium resonium, which is used to treat hyperkalaemia over a short-term in chronic kidney disease, is associated with the development of which one of the following conditions?
Deficiency of which of the following mineral(s) can lead to hypocalcemia by impairing the ability of the parathyroid gland to secrete parathyroid hormone?
1. Phosphate
2. Magnesium
3. Sodium
4. Potassium
Select the correct answer using the code given below:
Important Questions from Electrolyte Imbalance
- Which of the following does NOT cause prolongation of QT interval?
- Which of the following does NOT causes polyuria?
- A 36-year old chronic alcoholic, malnourished male is hospitalized with pneumonia. His condition worsens after aggressive treatment with intravenous dextrose and antibiotics. This phenomenon of 'Refeeding Syndrome' is accompanied by which one of the following biochemical alterations?
- Which one of the following drugs causes hypercalcemia?
- Syndrome of Inappropriate ADH secretion (SIADH) is usually associated with:
